膀胱癌临床试验招募信息（全球在招）
这里汇总了全球正在招募患者的 膀胱癌（国际通用名 bladder cancer）新药临床试验，包含试验分期、招募状态、开展国家和研究团队联系方式，全部以中文呈现。数据实时来自全球最大的临床试验注册库 ClinicalTrials.gov。本页同时覆盖尿路上皮癌等说法。
正在招募的膀胱癌新药试验
Multicentric Prospective T1 Urinary Bladder Cancer Registry
不适用招募中AustriaNCT05792033Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma
II 期招募中中国香港NCT06257017Outpatient Laser Ablation of Recurrent Non-muscle Invasive Bladder Cancer
不适用招募中DenmarkNCT05337397A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
II 期招募中美国澳大利亚加拿大中国NCT06760819Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial
I 期 / II 期招募中美国NCT07579195Validation of a Circulating Tumor DNA Blood Test in Muscle-Invasive Bladder and Upper Tract Urothelial Cancer
不适用招募中BelgiumNCT07756437Cancer Loyalty Card Study 2 (CLOCS-2)
不适用招募中英国NCT06447064Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients
不适用招募中法国NCT03787056CONFIRM: Magnetic Resonance Guided Radiation Therapy
不适用招募中美国NCT04368702Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients Without Progression and With no More Than Three Residual Metastatic Lesions Following First Line Systemic Therapy
II 期招募中法国NCT04428554NEO-BLAST: Neoadjuvant Therapy for Bladder Cancer Followed by Active Surveillance vs Treatment
II 期 / III 期招募中加拿大NCT06537154Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
不适用招募中美国NCT06349642
膀胱癌试验不在中国大陆，还能参加吗？
可以尝试四条现实路径：查找国内同类试验、申请同情用药与扩展准入、赴境外研究中心入组、直接写信给申办方申请在华开展。本站提供中英文对照的咨询信模板，患者和家属填写基本情况即可生成。